{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:27Z","timestamp":1793045487892,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>While metabolic pathway alterations are linked to colorectal cancer (CRC), the predictive value of pre-diagnostic metabolomic profiling in CRC risk assessment remains to be clarified. This study evaluated the predictive performance of a metabolomics risk panel (MRP) both independently and in combination with established risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We derived, internally validated (IV), and externally validated (EV) a metabolomics risk panel (MRP) for CRC from data of the UK Biobank (UKB) and the German ESTHER cohort. Baseline blood samples were assessed for 249 metabolites using nuclear magnetic resonance spectroscopy analysis. We applied LASSO Cox proportional hazards regression to identify metabolites for inclusion in the MRP and evaluated the model performance using the concordance index (C-index). We compared the performance of the MRP to an environmental risk panel (ERP; sex, age, body mass index, smoking status, and alcohol consumption) and a genetic risk panel (GRP; polygenic risk score).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included 154,892 participants of the UKB cohort (mean age at baseline 54.5 years; 55.5% female) with 1879 incident CRC and 3242 participants of the ESTHER cohort (mean age 61.5 years; 52.2% female) with 103 CRC cases. Twenty-three metabolites, primarily amino acid and lipid-related metabolites, were selected for the MRP, showing moderate predictive performance (C-index 0.60 [IV] and 0.54 [EV]). The ERP and GRP showed superior performance, with C-index values of 0.73 (IV) and 0.69 (EV). Adding the MRP to these risk models did not change the C-indices in both cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Genetic and environmental risk information provided strong predictive accuracy for CRC risk, with no improvements from adding metabolomics data. These findings suggest that metabolomics data may have limited impact on enhancing established CRC risk models in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-025-04107-w","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:49:50Z","timestamp":1747147790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring metabolomics for colorectal cancer risk prediction: evidence from the UK Biobank and ESTHER cohorts"],"prefix":"10.1186","volume":"23","author":[{"given":"Teresa","family":"Seum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Stevenson-Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Holleczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sch\u00f6ttker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"3","key":"4107_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10207","key":"4107_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0.","journal-title":"Lancet"},{"key":"4107_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5383","volume":"367","author":"M Buskermolen","year":"2019","unstructured":"Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019;367: l5383. https:\/\/doi.org\/10.1136\/bmj.l5383.","journal-title":"BMJ"},{"key":"4107_CR4","doi-asserted-by":"crossref","unstructured":"Mina PR. Metabolomics approach to identify biomarkers of epidemic diseases. In: Soni V, Hartman TE, editors. Metabolomics. Cham: Springer International Publishing; 2023. p. 93\u2013126.","DOI":"10.1007\/978-3-031-39094-4_4"},{"issue":"4","key":"4107_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21670","volume":"71","author":"DR Schmidt","year":"2021","unstructured":"Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin. 2021;71(4):333\u201358. https:\/\/doi.org\/10.3322\/caac.21670.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4107_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030725","volume":"14","author":"A Gold","year":"2022","unstructured":"Gold A, Choueiry F, Jin N, Mo X, Zhu J. The application of metabolomics in recent colorectal cancer studies: a state-of-the-art review. Cancers (Basel). 2022;14(3): 725. https:\/\/doi.org\/10.3390\/cancers14030725.","journal-title":"Cancers (Basel)"},{"key":"4107_CR7","doi-asserted-by":"publisher","unstructured":"Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review. Cancers (Basel). 2018;10(8). https:\/\/doi.org\/10.3390\/cancers10080246.","DOI":"10.3390\/cancers10080246"},{"key":"4107_CR8","doi-asserted-by":"publisher","unstructured":"Harlid S, Gunter MJ, Van Guelpen B. Risk-predictive and diagnostic biomarkers for colorectal cancer; a systematic review of studies using pre-diagnostic blood samples collected in prospective cohorts and screening settings. Cancers (Basel). 2021;13(17). https:\/\/doi.org\/10.3390\/cancers13174406.","DOI":"10.3390\/cancers13174406"},{"issue":"3","key":"4107_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2020.07.006","volume":"107","author":"M Thomas","year":"2020","unstructured":"Thomas M, Sakoda LC, Hoffmeister M, Rosenthal EA, Lee JK, van Duijnhoven FJB, et al. Genome-wide modeling of polygenic risk score in colorectal cancer risk. Am J Hum Genet. 2020;107(3):432\u201344. https:\/\/doi.org\/10.1016\/j.ajhg.2020.07.006.","journal-title":"Am J Hum Genet"},{"issue":"49","key":"4107_CR10","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1055\/s-2004-836089","volume":"129","author":"M Low","year":"2004","unstructured":"Low M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H, ESTHER study. [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)]. Dtsch Med Wochenschr. 2004;129(49):2643\u20137. https:\/\/doi.org\/10.1055\/s-2004-836089.","journal-title":"Dtsch Med Wochenschr"},{"issue":"7726","key":"4107_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0579-z.","journal-title":"Nature"},{"key":"4107_CR12","doi-asserted-by":"publisher","unstructured":"Thompson DJ, Wells D, Selzam S, Peneva I, Moore R, Sharp K, et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.06.16.22276246.","DOI":"10.1101\/2022.06.16.22276246"},{"issue":"1","key":"4107_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13148-017-0387-6","volume":"9","author":"X Gao","year":"2017","unstructured":"Gao X, Thomsen H, Zhang Y, Breitling LP, Brenner H. The impact of methylation quantitative trait loci (mQTLs) on active smoking-related DNA methylation changes. Clin Epigenetics. 2017;9(1):87. https:\/\/doi.org\/10.1186\/s13148-017-0387-6.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4107_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8(1):192\u2013206. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000216.","journal-title":"Circ Cardiovasc Genet"},{"issue":"9","key":"4107_CR15","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1039\/b910205a","volume":"134","author":"P Soininen","year":"2009","unstructured":"Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134(9):1781\u20135. https:\/\/doi.org\/10.1039\/b910205a.","journal-title":"Analyst"},{"issue":"9","key":"4107_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P Wurtz","year":"2017","unstructured":"Wurtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am J Epidemiol. 2017;186(9):1084\u201396. https:\/\/doi.org\/10.1093\/aje\/kwx016.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"4107_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-Statistical Methodology. 1995;57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"Journal of the Royal Statistical Society Series B-Statistical Methodology"},{"issue":"7","key":"4107_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2468-1253(22)00044-9","volume":"7","author":"R Sharma","year":"2022","unstructured":"Sharma R, Abbasi-Kangevari M, Abd-Rabu R, Abidi H, Abu-Gharbieh E, Acuna JM, et al. Global, regional, and national burden of colorectal cancer and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology. 2022;7(7):627\u201347. https:\/\/doi.org\/10.1016\/S2468-1253(22)00044-9.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"3","key":"4107_CR19","doi-asserted-by":"publisher","first-page":"pkac027","DOI":"10.1093\/jncics\/pkac027","volume":"6","author":"E Loftfield","year":"2022","unstructured":"Loftfield E, Falk RT, Sampson JN, Huang WY, Hullings A, Murphy G, et al. Prospective associations of circulating bile acids and short-chain fatty acids with incident colorectal cancer. JNCI Cancer Spectr. 2022;6(3):pkac027. https:\/\/doi.org\/10.1093\/jncics\/pkac027.","journal-title":"JNCI Cancer Spectr."},{"issue":"6","key":"4107_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1158\/1055-9965.Epi-21-1008","volume":"31","author":"X Shu","year":"2022","unstructured":"Shu X, Chen ZS, Long JR, Guo XY, Yang YH, Qu CH, et al. Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk. Cancer Epidemiol Biomark Prev. 2022;31(6):1216\u201326. https:\/\/doi.org\/10.1158\/1055-9965.Epi-21-1008.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"4107_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ijc.31341","volume":"143","author":"X Shu","year":"2018","unstructured":"Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, et al. Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 2018;143(3):527\u201334. https:\/\/doi.org\/10.1002\/ijc.31341.","journal-title":"Int J Cancer"},{"key":"4107_CR22","doi-asserted-by":"publisher","unstructured":"Barrett JC, Esko T, Fischer K, Jostins-Dean L, Jousilahti P, Julkunen H, et al. Metabolomic and genomic prediction of common diseases in 477,706 participants in three national biobanks. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.06.09.23291213.","DOI":"10.1101\/2023.06.09.23291213"},{"issue":"5","key":"4107_CR23","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1016\/j.cgh.2020.11.045","volume":"20","author":"JA Rothwell","year":"2022","unstructured":"Rothwell JA, Murphy N, Besevic J, Kliemann N, Jenab M, Ferrari P, et al. Metabolic signatures of healthy lifestyle patterns and colorectal cancer risk in a European cohort. Clin Gastroenterol Hepatol. 2022;20(5):e1061\u201382. https:\/\/doi.org\/10.1016\/j.cgh.2020.11.045.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4107_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201606","volume":"218","author":"X Bian","year":"2020","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2020;218(1): e20201606. https:\/\/doi.org\/10.1084\/jem.20201606.","journal-title":"J Exp Med"},{"issue":"1","key":"4107_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","volume":"52","author":"EL Lieu","year":"2020","unstructured":"Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med. 2020;52(1):15\u201330. https:\/\/doi.org\/10.1038\/s12276-020-0375-3.","journal-title":"Exp Mol Med"},{"key":"4107_CR26","doi-asserted-by":"publisher","unstructured":"Cheng H, Wang M, Su J, Li Y, Long J, Chu J, et al. Lipid metabolism and cancer. Life (Basel). 2022;12(6). https:\/\/doi.org\/10.3390\/life12060784.","DOI":"10.3390\/life12060784"},{"issue":"6","key":"4107_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052373","volume":"12","author":"Z Yang","year":"2022","unstructured":"Yang Z, Tang H, Lu S, Sun X, Rao B. Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis. BMJ Open. 2022;12(6): e052373. https:\/\/doi.org\/10.1136\/bmjopen-2021-052373.","journal-title":"BMJ Open"},{"issue":"1","key":"4107_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13578-023-00977-w","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zou S, Fang L. Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell Biosci. 2023;13(1):25. https:\/\/doi.org\/10.1186\/s13578-023-00977-w.","journal-title":"Cell Biosci"},{"issue":"6","key":"4107_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/metabo10060229","volume":"10","author":"R Gonzalez-Dominguez","year":"2020","unstructured":"Gonzalez-Dominguez R, Gonzalez-Dominguez A, Sayago A, Fernandez-Recamales A. Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics. Metabolites. 2020;10(6): 229. https:\/\/doi.org\/10.3390\/metabo10060229.","journal-title":"Metabolites"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04107-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:49:53Z","timestamp":1747147793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04107-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Biobank: Ethics approval for data collection was obtained by the data source UK Biobank. All participants provided written informed consent, and ethical approval was obtained from the North West Multicentre Research Ethics Committee (MREC). This research has been conducted in the framework of the UK Biobank application no. 101633 \u201cUse of omics data to understand better the etiology of age-related diseases and to improve their risk prediction.\u201dESTHER: The ESTHER study has been approved by the ethics committees of the Medical Faculty of Heidelberg University (reference number: S-58\/200) and of the state medical board of Saarland, Germany. Written informed consent was obtained from all participants. The study is being conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}